AI Verdict
KALV has stronger fundamentals based on our AI analysis.
KALV vs KALA Fundamental Comparison
| Metric | KALV | KALA |
|---|---|---|
| Revenue | $13.7M | $0.0 |
| Net Income | $-158.9M | $-27.7M |
| Net Margin | -1,160.0% | N/A |
| ROE | -934.8% | N/A |
| ROA | -46.7% | -110.6% |
| Current Ratio | 7.22x | 0.75x |
| Debt/Equity | 0.31x | N/A |
| EPS | $-2.97 | $-4.17 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
KALV vs KALA: Frequently Asked Questions
Is KALV or KALA a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), KALV has stronger fundamentals. KALV is rated HOLD (45% confidence) while KALA is rated STRONG SELL (88% confidence). This is not investment advice.
How does KALV compare to KALA fundamentally?
KalVista Pharmaceuticals, Inc. has ROE of -934.8% vs KALA BIO, Inc.'s N/A. Net margins are -1,160.0% vs N/A respectively.
Which stock pays higher dividends, KALV or KALA?
KALV has a dividend yield of N/A or no dividend while KALA has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in KALV or KALA for long term?
For long-term investing, consider that KALV has HOLD rating with 45% confidence, while KALA has STRONG SELL rating with 88% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about KALV vs KALA?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For KALV vs KALA, the AI consensus favors KALV based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.